林水賓
林水賓
職稱：研究員
科室：轉(zhuǎn)化醫(yī)學研究中心
學位/學歷：博士
導師資格：博士生導師
職務(wù)：?？浦魅?/div>
出診時間
專家門診
周一
Mon
周二
Tue
周三
Wed
周四
Thur
周五
Fri
周六
Sat
周日
Sun
上午
AM
下午
PM
出診時間以實際為準

科研特長：

      國家杰出青年,、優(yōu)秀青年科學基金獲得者，國家重點研發(fā)計劃國合重點專項首席科學家,，廣東省杰青,，廣東省珠江人才計劃青年拔尖人才。美國基因和細胞治療協(xié)會會刊Molecular Therapy 雜志 (Cell Press,，IF=12.1)副主編,。從事腫瘤mRNA翻譯異常調(diào)控的致病功能和機制研究，以通訊/第一作者（共同）發(fā)表Nature, Nature Metabolism, Molecular Cell (3篇), Nature Protocols, Nature Communications (2篇),，Cell Reports等論文20多篇, 受邀為Nature Reviews撰寫綜述,。多次入選“中國高被引學者”和“全球前2%頂尖科學家”榜單,。

 

研究方向：

      1）mRNA翻譯異常對腫瘤和干細胞的調(diào)控功能和機制研究；2）新型翻譯調(diào)控因子鑒定和功能研究,；3）mRNA翻譯異常相關(guān)疾病的診療干預轉(zhuǎn)化醫(yī)學研究,。

 

主要教育和工作經(jīng)歷：

      2000-2004 學士 福建省廈門大學生命科學學院，國家生物科學人才培養(yǎng)基地班

      2004-2007 碩士 福建省廈門大學生命科學學院,，生物醫(yī)學科學系

      2007-2012 博士 美國佛羅里達大學醫(yī)學院（College of Medicine, University of Florida, USA）

      2012-2017 博士后 美國哈佛大學醫(yī)學院,，波士頓兒童醫(yī)院 (Harvard Medical School, Boston Children's Hospital)

      2017-至今  中山大學附屬第一醫(yī)院轉(zhuǎn)化醫(yī)學研究中心工作

 

論著：

  1. Lin S#, Kuang M#. RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives. Nature Reviews Gastroenterology & Hepatology. 2024 Apr;21(4):267-281. doi: 10.1038/s41575-023-00884-y.
  2. Wei W*, Zhang S*, Han H*, Wang X, Zheng S, Wang Z, Yang C, Wang L, Ma J, Guo S, Wang J, Liu L, Choe J, Lin S. NAT10-mediated ac4C tRNA modification promotes EGFR mRNA translation and gefitinib resistance in cancer. Cell Reports. 2023 Jul 25;42(7):112810.
  3. Wang Z*, Yu P*, Zou Y*, Ma J, Han H, Wei W, Yang C, Zheng S, Guo S, Wang J, Liu L, Lin S. METTL1/WDR4-mediated tRNA m7G modification and mRNA translation control promote oncogenesis and doxorubicin resistance. Oncogene. 2023 Jun; 42(23):1900-1912.
  4. Liu H*, Zeng X*, Ren X*, Zhang Y*, Huang M*, Tan L, Dai Z, Lai J, Xie W, Chen Z, Peng S, Xu L, Chen S, Shen S#, Kuang M#, Lin S#. Targeting tumor-intrinsic N7-methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy. Gut. 2023 Aug;72(8):1555-1567.
  5. Peng H*, Chen B*, Wei W*, Guo S*, Han H, Yang C, Ma J, Wang L, Peng S#, Kuang M#, Lin S#. N6-methyladenosine (m6A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation. Nature Metabolism. 2022 Aug;4(8):1041-1054.
  6. Han H*, Zheng S*, Lin S. N7-methylguanosine (m7G) tRNA modification: a novel autophagy modulator in cancer. Autophagy. 2022 May 23:1-3.
  7. Han H*, Yang C*, Ma J*, Zhang S*, Zheng S*, Ling R, Sun K, Guo S, Huang B, Liang Y, Wang L, Chen S, Wang Z, Wei W, Huang Y, Peng H, Jiang YZ, Choe J, Lin S. N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis. Nature Communications. 2022 Mar 18;13(1):1478.
  8. Su T, Cheng F, Qi J, Zhang Y, Zhou S, Mei L, Fu S, Zhang F, Lin S#, Zhu G#. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy. Advanced Science. 2022 Jun 16;e2201895.
  9. Yang C, Han H, Lin S. RNA epitranscriptomics: A promising new avenue for cancer therapy. Molecular Therapy. 2022 Jan 5;30(1):2-3.
  10. Chen Z*, Zhu W*, Zhu S*, Sun K, Liao J, Liu H, Dai Z, Han H, Ren X, Yang Q, Zheng S, Peng B, Peng S, Kuang M#, Lin S#. METTL1 promotes hepatocarcinogenesis via m7G tRNA modification-dependent translation control. Clinical and Translational Medicine. 2021 Dec;11(12):e661.
  11. Dai Z*, Liu H*, Liao J*, Huang C*, Ren X*, Zhu W, Zhu S, Peng B, Li S, Lai J, Liang L, Xu L, Peng S, Lin S#, Kuang M#. N7-methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression. Molecular Cell. 2021 Aug 19;81(16):3339-3355.
  12. Ma J*, Han H*, Huang Y*, Yang C, Zheng S, Cai T, Bi J, Huang X, Liu R, Huang L, Luo Y#, Li W#, Lin S#. METTL1/WDR4 mediated N7-methylguanosine (m7G) tRNA modifications and m7G codon usage promote mRNA translation and lung cancer progression. Molecular Therapy. 2021 Aug 8:S1525- 0016(21)00399-3.
  13. Han H*, Yang C*, Zhang S*, Cheng M*, Guo S, Zhu Y, Ma Y, Liang Y, Wang L, Zheng S, Wang Z, Chen D#, Jiang YZ#, Lin S#. METTL3 mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway. Molecular Therapy-Nucleic Acids. 2021 Jul 21; 26:333-346.
  14. Lin S#, Liu Q, Jiang YZ, Gregory RI#. Nucleotide resolution profiling of m7G tRNA modification by TRAC-Seq. Nature Protocols. 2019 Nov; 14: 3220–3242.
  15. Wu Y*, Xie L*, Wang M, Xiong Q, Guo Y, Liang Y, Li J, Sheng R, Deng P, Wang Y, Zheng R, Jiang Y, Ye L, Chen Q, Zhou X#, Lin S#, Quan Y#. Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nature Communications 2018. 9:4772.
  16. Choe J*, Lin S*, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, Santisteban P, George RE, Richards WG, Wong KK, Locker N, Slack FJ, Gregory RI. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 2018 Sep;561(7724):556-560
  17. Lin S*, Liu Q*, Lelyveld VS, Choe J, Szostak JW, Gregory RI. The Mettl1/Wdr4 mediated m7G tRNA methylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation. Molecular Cell. 2018 Jul 19;71(2):244-255.
  18. Lin S*, Choe J*, Du P, Triboulet R, Gregory RI. The m6A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. Molecular Cell. 2016 May 5; 62(3):335-345. Highlighted in Mol Cell. 2016 May 5; 62(3):323-324 and Cancer Discov. 2016 Jun; 6(6):572.
  19. Lin S, Gregory RI. MicroRNA biogenesis in cancers. Nature Reviews Cancer. 2015 Jun; 15(6):321-33.
  20. Lin S, Gregory RI. Methyl-transferases modulate RNAs stability in embryonic stem cells. Nature Cell Biology. 2014 Feb;16(2):129-31.
  21. Su T*, Zhang Y*, Valerie K, Wang XY, Lin S#, Zhu G#. STING activation in cancer immunotherapy. Theranostics. 2019 Oct 15;9(25):7759-7771.
  22. Lin S, Gregory RI. Identification of small molecule inhibitors of Zcchc11 TUTase activity. RNA Biology. 2015;12(8):792-800.
  23. Lin S*, Tian L*, Shen H*, et.al. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia. Oncogene. 2013 Oct;32(40):4845-53.
  24. Lin S, Shen H, Jin B, et.al. Blockade of Notch Signaling in Muscle Stem Cells Causes Muscular Dystrophic Phenotype and Impaired Muscle Regeneration. Stem Cells. 2013 Apr;31(4):823-8.
  25. Lin S, Shen H, Li JL, et.al. Proteomic and functional analyses reveal the chromatin reader SFMBT1's role in regulating epigenetic silencing and the myogenic gene program. Journal of Biological Chemistry. 2013 Mar 1;288(9):6238-47.

 

其他主要工作成績：

      2013 Damon Runyon-Sohn Pediatric Fellowship Award, Damon Runyon Cancer Research Foundation

      2017 Young Investigator award, Alex's Lemonade Stand Foundation